Prediction of an Occurrence of a Cardiac Arrhythmia Based on Nerve Growth Factor

Tech ID: che000438



Sudden cardiac death (SCD) is a major public health problem that accounts for more than half of all cardiovascular deaths. SCD takes the lives of approximately 450,000 people in the United States each year, more than lung cancer, breast cancer, stroke, and AIDS combined. Most cases of SCD are due to ventricular arrhythmias and there is often an element of underlying ischemic heart disease. Different treatment options exist for SCD. The most common treatment includes implantable cardiac defibrillators (ICD) and drug therapy. Current ICD technology, however, provides for the detection and recognition of an arrhythmia based on the sensed heart rate once it has already started. This leaves very little time to protect the individual from death resulting from SCD. Although there have been several attempts at developing new technology for predicting the onset of a cardiac arrhythmia, many of these methods and systems appear to rely primarily on events occurring within the heart, such as sensed heart rate and electrocardiography (ECG).


Technology Description

To fulfill the demand for a better method for the prediction of an arrhythmia, Dr. Chen from Cedars-Sinai Medical Center developed a method and a kit to measure the plasma and/or serum levels of nerve growth factor or NGF in a patient and detecting increases in plasma and/or serum level NGF as a predictor of cardiac arrhythmias. For example, patients' peripheral veins may be used to obtain small amounts of serum for detection and measurement of NGF levels.


Stage of Development

Animal data



The methods of the present invention allow for the timely institution of preventive therapy for arrhythmia and/or SCD. A significant advantage of the present invention is its speed and non-invasiveness.



Prediction of an arrhythmia


Intellectual Property

•       US patent 7822474 granted.

Patent Information:
For Information, Contact:
Julien Brohan
Peng-Sheng Chen